Where can I find the protein concentration?

The protein concentration of each product is listed on the Certificate of Analysis. This value is determined for each individual lot and reflects the actual concentration (mg/mL) of the material you received.

Where can I find the recommended storage conditions?

Storage conditions are listed on both the product datasheet and the Certificate of Analysis. These recommendations are based on internal stability assessments and are intended to maintain protein integrity and activity.

What should I do if my product arrives warm, partially thawed, or damaged?

Please contact Athens Bioscience with your order number and lot number. Our technical support team will assist you promptly.

Where can I find the final buffer composition?

The final buffer formulation is provided on the Certificate of Analysis. This includes buffer components, pH, and whether the product was supplied as a liquid or lyophilized powder.

Immunoglobulin G1, Myeloma

Name: Immunoglobulin G1, Myeloma
SKU: 16-16-090707-1M-1MG
Availability: InStock

IgG1 Myeloma

The predominant IgG subclass, constituting 65% of serum IgG. Characterized by a flexible hinge region, IgG1 possesses broad antigen recognition with potent effector functions.

Purity: ≥95% (SDS-PAGE)

Source: Human Myeloma Plasma

Molecular Weight: 146 kDa

Form: Frozen

View All Specifications

Bulk Quotation Request

Product Description

Role of protein in biology

IgG1, constituting 65% of serum IgG, is the predominant subclass critical for adaptive immunity, characterized by a flexible hinge region enabling broad antigen recognition and potent effector functions. Its Fc domain binds FcγRI/III receptors and C1q, driving antibody-dependent cellular cytotoxicity (ADCC), phagocytosis, and complement activation. In multiple myeloma, monoclonal IgG1 overproduction disrupts normal immunoglobulin synthesis, often manifesting as renal impairment or hyperviscosity syndrome. Serum IgG1 quantification aids in monitoring disease progression and treatment efficacy, with elevated ratios of IgG1/IgG (>65%) signaling clonal plasma cell expansion.

Common research uses

Autoimmune pathologies like systemic lupus erythematosus (SLE) and Sjögren’s syndrome exhibit IgG1-predominant autoantibodies targeting nuclear antigens, exacerbating tissue inflammation via FcγR-mediated leukocyte activation. Conversely, IgG1 deficiencies (<4.9 g/L) predispose to recurrent bacterial infections due to impaired opsonization of protein antigens like tetanus toxoid. Therapeutically, myeloma-derived IgG1 serves as a standardized reagent in immunoassays and structural studies, leveraging its intact glycosylation patterns. Dysregulated IgG1 also underpins type II hypersensitivity reactions, with FcγRIII cross-linking on mast cells/basophils driving anaphylactic pathways. By balancing immune activation and homeostasis, IgG1 remains pivotal in both pathogenic mechanisms and biotherapeutic innovation.

Common uses include ELISA standards, IVD Assay standards, calibrators and controls, therapeutics research, immune system research, flow cytometry assays.